Q-omics provides the consensus-scored ZAN profile across patient tissues and cancer cell-line models. ZAN expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZAN is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ZAN RNA expression shows 13,639 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where ZAN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZAN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZAN survival associations across molecular data types. ZAN RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZAN RNA expression–survival associations across cancer types. High ZAN expression shows unfavorable associations in ACC, KIRC, SCLC and KICH, but favorable associations in HNSC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZAN RNA expression.
This table summarizes ZAN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZAN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZAN shows lower tumor expression in THCA and LIHC and higher tumor expression in HNSC, BRCA, LUSC and COAD. The HNSC box plot shows higher ZAN RNA expression in tumor versus normal tissue (log2 FC = +0.758, t-test p < 0.001).
This table shows molecular features associated with ZAN in patient tissues and cancer cell lines. In patient samples, ZAN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZAN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
